Back to News
Market Impact: 0.35

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

Source: PR Newswire

Healthcare & BiotechCompany Fundamentals

Etentamig reported a significantly improved objective response rate (ORR) of 74% and a 60% reduction in risk of disease progression or death, with progression-free survival showing a hazard ratio of 0.40 versus investigator's choice of standard available therapies.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

strongly positive

Sentiment Score

0.55

More News

From AllMind Research

Browse all research